{
    "nctId": "NCT04252768",
    "briefTitle": "A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel",
    "officialTitle": "AIPAC-002 (Active Immunotherapy PAClitaxel-002): A Multicentre, Phase Ib Study to Test a New Schedule of Eftilagimod Alpha (a Soluble LAG-3 Protein) as Adjunctive to Weekly Paclitaxel in Hormone Receptor-positive Metastatic Breast Carcinoma Patients",
    "overallStatus": "WITHDRAWN",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Safety and tolerability profile of efti in combination with weekly paclitaxel both given the same day",
    "eligibilityCriteria": "Inclusion Criteria (selected ones):\n\n* Metastatic oestrogen receptor positive and/or progesterone receptor positive breast adenocarcinoma, histologically proven by biopsy of the primary tumour and/or a metastasis\n* Subjects who are indicated to receive first line chemotherapy with weekly paclitaxel\n* ECOG performance status 0-1\n* Expected survival longer than three months\n\nExclusion Criteria (selected ones):\n\n* Prior chemotherapy for metastatic breast adenocarcinoma\n* Disease-free interval of less than twelve months from the last dose of adjuvant chemotherapy\n* Prior high-dose chemotherapy requiring hematopoietic stem cell rescue\n* Inflammatory carcinoma at time of screening\n* Candidate for treatment with trastuzumab (or other Her2/neu targeted agents) or endocrine based therapy according to the applicable treatment guidelines\n* Systemic chemotherapy, radiation therapy or any other investigational agent within 4 weeks, endocrine therapy within 1 week or CDK4/6 inhibitors within 5 times half-life (acc. to SPC) prior to first dose of study treatment\n* Symptomatic known cerebral and/or leptomeningeal metastases",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}